Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-VEGFR2 monoclonal antibody HLX06

A fully human monoclonal antibody directed against human vascular endothelial growth factor receptor 2 (VEGFR-2) with potential anti-angiogenesis and antineoplastic activities. Upon administration, anti-VEGFR2 monoclonal antibody HLX06 specifically binds to and inhibits VEGFR-2, which may inhibit tumor angiogenesis and tumor cell proliferation. VEGFR-2, a tyrosine-protein kinase that plays an essential role in angiogenesis and the proliferation, survival, migration and differentiation of endothelial cells, is overexpressed in certain tumor types.
Code name:HLX 06
HLX-06
HLX06
Search NCI's Drug Dictionary